The Food and Drug Administration has ordered Silicon Valley gene-testing service 23andMe to halt all sales and marketing of its gene testing kits. 23andMe led the way in the personal-genomics revolution after it was declared Time Magazine’s 2008 invention of the year, but regulators have concerns that inaccurate results from the direct-to-consumer tests, or results that are not adequately understood by patients, could lead to dangerous decisions. Forum discusses the FDA’s order and the future of personal gene tests.
Hank Greely, director of the Center for Law and the Biosciences and law professor at Stanford University
Christina Farr, health reporter for Venture Beat
Nita Farahany, professor of genome sciences and policy and law professor at Duke University; also a member of the Presidential Commission for the Study of Bioethical Issues
Courtney Lias, director of chemistry and toxicology devices at the Center for Devices and Radiological Health at the Food and Drug Administration